RVTY — Revvity, Inc.

Revvity (RVTY) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Q4 Revenue: $772 million, representing 4% organic growth.
• Full Year Revenue: $2.86 billion, with 3% organic growth.
• Adjusted EPS (Q4): $1.70, exceeding guidance by $0.11.
• Full Year Adjusted EPS: $5.06, surpassing the high end of guidance and reflecting 3% growth year-over-year.
• Adjusted Operating Margins (Q4): 29.7%, slightly down from the previous year but in line with expectations.
• Free Cash Flow (Q4): $162 million, with 84% conversion of adjusted net income; full year free cash flow was $515 million (87% conversion).

2. Strategic Updates and Business Highlights:

• The diagnostics segment saw a strong performance with a 7% organic growth in Q4, driven by reproductive health and immunodiagnostics.
• Life sciences segment was flat year-over-year, with low single-digit growth from pharma customers but a decline from academic and government customers.
• Revvity completed the acquisition of ACD Labs, expected to contribute over $20 million to revenue in 2026.
• The company is launching an AI models platform, Signals Synthetica, aimed at enhancing drug development efficiency.

3. Forward Guidance and Outlook:

• For 2026, Revvity anticipates organic growth in the range of 2% to 3%, with total revenue projected between $2.96 billion and $2.99 billion.
• Adjusted EPS for 2026 is expected to be between $5.35 and $5.45, indicating high single-digit growth.
• The company plans to maintain adjusted operating margins at 28% for the year, with improvements expected in the second half as cost efficiency initiatives take effect.

4. Bad News, Challenges, or Points of Concern:

• Continued headwinds from external factors such as NIH funding changes, tariffs, and pressures in the Chinese market, particularly in diagnostics.
• The life sciences segment is facing challenges from a decline in academic and government sales, and there is uncertainty regarding the recovery of the China IDX business.
• The company has adopted a conservative outlook, reflecting cautious optimism about market recovery and potential upside.

5. Notable Q&A Insights:

• Management acknowledged the cautious optimism in the pharma and biotech sectors, noting improvements in funding and M&A activity.
• There was discussion on the potential for upside in organic growth, particularly from life sciences and diagnostics, but management emphasized a prudent approach to guidance.
• The company is not currently modeling significant improvements in preclinical markets but is open to adjusting forecasts if market conditions improve.
• Competitive dynamics in the reagents market appear stable, with no significant margin pressures reported.
• Management expressed confidence in the integration of ACD Labs and the potential of the new AI platform to enhance growth.

Overall, Revvity's Q4 2025 results reflect a resilient performance amidst various challenges, with a cautiously optimistic outlook for 2026 driven by strategic initiatives and market recovery potential.